FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma

FDA

22 March 2023 - Today the FDA granted accelerated approval to retifanlimab-dlwr (Zynyz, Incyte) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.

Safety and efficacy were evaluated in PODIUM-201, an open-label, multi-regional, single-arm study evaluating 65 patients with metastatic or recurrent locally advanced Merkel cell carcinoma who had not received prior systemic therapy for advanced disease.

Read FDA News

Michael Wonder

Posted by:

Michael Wonder